Athira Pharma Highlights Therapeutic Potential of Fosgonimeton for Alzheimer’s, Parkinson’s Diseases
Late clinical-stage biopharmaceutical company, Athira Pharma, Inc. (Nasdaq: ATHA), has presented new clinical data highlighting the therapeutic potential of fosgonimeton at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders.
Mark Litton, Ph.D., President and Chief Executive Officer of Athira, said, “Data presented at AD/PD, in tandem with the existing body of preclinical and clinical evidence, continue to support the potential of targeting the neurotrophic HGF system to treat neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease and dementia with Lewy bodies. We believe safety and efficacy outcomes from the exploratory SHAPE Phase 2 clinical trial presented at this year’s AD/PD, along with previous clinical data, support the continued development of fosgonimeton.”
Athira expects to release data from its Phase 2/3 LIFT-AD trial, which is evaluating fosgonimeton at 40 mg as a potential treatment for mild-to-moderate Alzheimer’s disease, in the second half of 2024.
Highlights
Athira’s SHAPE study was a randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial for ATH-1017 (fosgonimeton) in subjects with Parkinson’s disease dementia or dementia with Lewy bodies. The study enrolled 28 subjects.
Fosgonimeton is a potentially first-in-class investigational small molecule designed to positively modulate the hepatocyte growth factor (HGF) system, which can activate neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system.
About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer’s disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn, X (formerly known as Twitter) and Instagram.
